Literature DB >> 12749946

Effect of heparin on cleavage rates and embryo production with four bovine sperm preparation protocols.

J O B Mendes1, P D Burns, J F De La Torre-Sanchez, G E Seidel.   

Abstract

Heparin is often added to fertilization media to induce sperm capacitation. However, recent observations from the bovine IVF industry have indicated that heparin may not be necessary to induce sperm capacitation when cryopreserved bovine sperm are separated through Percoll gradients. The objective of these studies was to determine if the addition of heparin to fertilization media was required following separation of frozen-thawed bovine sperm. Experiment 1 was conducted to determine the effect of heparin on cleavage rates and embryo production when using Percoll, BSA or washing sperm separation protocols. Experiment 2 was conducted to determine the effect of heparin on cleavage rates and embryonic development when using a new sperm separation protocol (PureSperm). In Experiment 1, regardless of sperm separation protocol, heparin increased cleavage rates and embryo production (P<0.05). Further, cleavage rates and embryo production were higher for the Percoll procedure compared to either BSA or washing sperm separation protocols (P<0.05). In Experiment 2, there was no difference between Percoll and PureSperm separation protocols on cleavage rates or embryo production (P>0.05). However, heparin increased cleavage rates for both protocols and improved embryo production for the PureSperm protocol (P<0.05). In conclusion, use of heparin in fertilization media improves in vitro embryo production when using cryopreserved bovine sperm. Furthermore, PureSperm can be used as an alternative to Percoll for bovine sperm separation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12749946     DOI: 10.1016/s0093-691x(03)00029-3

Source DB:  PubMed          Journal:  Theriogenology        ISSN: 0093-691X            Impact factor:   2.740


  6 in total

1.  Novel Synthetic oviductal fluid for Conventional Freezing 1 (SCF1) culture medium improves development and cryotolerance of in vitro produced Holstein embryos.

Authors:  Corie M Owen; Melissa A Johnson; Katherine A Rhodes-Long; Diana J Gumber; Moises Barceló-Fimbres; Joy L Altermatt; Lino Fernando Campos-Chillon
Journal:  J Anim Sci       Date:  2022-03-01       Impact factor: 3.159

2.  Heparin and penicillamine-hypotaurine-epinephrine (PHE) solution during bovine in vitro fertilization procedures impair the quality of spermatozoa but improve normal oocyte fecundation and early embryonic development.

Authors:  F S Gonçalves; L S S Barretto; R P Arruda; S H V Perri; G Z Mingoti
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-08-16       Impact factor: 2.416

3.  Effects of bovine spermatozoa preparation on embryonic development in vitro.

Authors:  Marko Samardzija; Martina Karadjole; Iva Getz; Zdenko Makek; Marijan Cergolj; Tomislav Dobranic
Journal:  Reprod Biol Endocrinol       Date:  2006-11-13       Impact factor: 5.211

4.  Significant heparin effect on bovine embryo development during sexed in vitro fertilization.

Authors:  Li-You An; Sanjeev A Chaubal; Yanhong Liu; Yexiang Chen; Tshimangadzo L Nedambale; Jie Xu; Fei Xue; Juan F Moreno; Shenghong Tao; Giorgio Antonio Presicce; Fuliang DU
Journal:  J Reprod Dev       Date:  2017-02-05       Impact factor: 2.214

5.  Bovine epididymal spermatozoa treatment for in vitro fertilization: Heparin accelerates fertilization and enables a reduction in coincubation time.

Authors:  Andrielle T M Cunha; José O Carvalho; Ana L S Guimarães; Ligiane O Leme; Felippe M Caixeta; João H M Viana; Margot A N Dode
Journal:  PLoS One       Date:  2019-01-07       Impact factor: 3.240

6.  The influence of Percoll® density gradient centrifugation before cryopreservation on the quality of frozen wisent (Bison bonasus) epididymal spermatozoa.

Authors:  Maria Eberhardt; Sylwia Prochowska; Anna M Duszewska; Ann Van Soom; Wanda Olech; Wojciech Niżański
Journal:  BMC Vet Res       Date:  2022-08-10       Impact factor: 2.792

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.